Synthetic peptides that could target and reduce toxic protein aggregateshave been developed by the researchers, which are supposed to cause Alzheimer’s disease. By the aggregation of the toxic protein Alzheimer's disease is caused. Amyloid beta is the protein made by Neurons in the human brain. For years, scientists believed that plaques triggered the cognitive impairments characteristic of Alzheimer disease. But new research implicated the small aggregates of amyloid beta as the toxic element of the disease. The synthetic peptides- which are designed to fold into a structure known as an alpha sheet- can block amyloid beta aggregation at the early and most toxic stage when oligomers form.The research showed that the synthetic alpha sheet's blocking activity reduced amyloid beta-triggered toxicity in human neural cells grown in culture, and inhibited amyloid beta oligomers in two laboratory animal models for Alzheimer's.These research shows that the growing consensus that amyloid beta oligomers not plaques are the toxic agents behind. The results also indicated that synthetic alpha sheets could form the basis of therapeutics to clear toxic oligomers in people. Daggett's team observed the individual stages of development of amyloid beta clusters, from monomers to six- and 12-protein oligomers all the way up to plaques, in human neural cell lines,using both novel and conventional spectroscopic techniques.The oligomers stages were most toxic to the neurons, which agrees with clinical reports of amyloid beta plaques in the brains of people who don't have Alzheimer's but more research instead indicates that amyloid beta oligomers are the toxic agents that disrupt neurons. The Researchers also created a novel laboratory assay for the current study, which that uses a synthetic alpha sheet to measure levels of amyloid beta oligomers. To detect toxic oligomers in people before the onset of Alzheimer's symptoms they believe that this assay could form the basis of a clinical test.